Ahlia Sekkarie1, Siran He2, Jean A Welsh3, Usha Ramakrishnan4, Aryeh D Stein5, Miriam B Vos3. 1. Nutrition and Health Sciences Program, Laney Graduate School, Emory University, Atlanta, GA, United States. Electronic address: asekkar@emory.edu. 2. Nutrition and Health Sciences Program, Laney Graduate School, Emory University, Atlanta, GA, United States. 3. Department of Pediatrics, Emory School of Medicine, Atlanta, GA, United States. 4. Nutrition and Health Sciences Program, Laney Graduate School, Emory University, Atlanta, GA, United States; Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, United States. 5. Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, GA, United States.
Abstract
INTRODUCTION AND OBJECTIVES: The global prevalence of non-alcoholic fatty liver disease (NAFLD) is approximately 25%, with Hispanic populations at greatest risk. We describe the prevalence of NAFLD in a cohort of Guatemalan adults and examine whether exposure to a protein-energy supplement from conception to two years is associated with lower prevalence of NAFLD. MATERIALS AND METHODS:From 1969 to 1977, four villages in Guatemala were cluster-randomized to receive a protein-energy supplement (Atole) or a no-protein, low-energy beverage (Fresco). We conducted a follow-up of participants from 2015 to 2017. We assessed blood samples (n=1093; 61.1% women; aged 37-53 years) for alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and estimated NAFLD prevalence using the liver fat score. We used generalized linear and logistic models to estimate the difference-in-difference effect of Atole from conception to two years on NAFLD. RESULTS:Median ALT and AST were 19.7U/L (interquartile range, IQR: 14.1, 27.4) and 26.0U/L (IQR: 21.4, 32.8), respectively. The median NAFLD liver fat score was 0.2 (IQR: -1.2, 1.6) in women and -1.2 (IQR: -2.2, 0.5) in men (p<0.0001). The prevalence of NAFLD was 67.4% among women and 39.5% among men (p<0.0001). The association between Atole exposure from conception to two years and NAFLD was not significant (OR: 0.90, 95% CI: 0.50-1.63). CONCLUSIONS:NAFLD prevalence among Guatemalan adults exceeds the global average. Protein-energy supplementation in early life was not associated with later NAFLD. There is a need for further studies on the causes and onset of NAFLD throughout the life course.
RCT Entities:
INTRODUCTION AND OBJECTIVES: The global prevalence of non-alcoholic fatty liver disease (NAFLD) is approximately 25%, with Hispanic populations at greatest risk. We describe the prevalence of NAFLD in a cohort of Guatemalan adults and examine whether exposure to a protein-energy supplement from conception to two years is associated with lower prevalence of NAFLD. MATERIALS AND METHODS: From 1969 to 1977, four villages in Guatemala were cluster-randomized to receive a protein-energy supplement (Atole) or a no-protein, low-energy beverage (Fresco). We conducted a follow-up of participants from 2015 to 2017. We assessed blood samples (n=1093; 61.1% women; aged 37-53 years) for alanine aminotransferase (ALT) and aspartate aminotransferase (AST) and estimated NAFLD prevalence using the liver fat score. We used generalized linear and logistic models to estimate the difference-in-difference effect of Atole from conception to two years on NAFLD. RESULTS: Median ALT and AST were 19.7U/L (interquartile range, IQR: 14.1, 27.4) and 26.0U/L (IQR: 21.4, 32.8), respectively. The median NAFLD liver fat score was 0.2 (IQR: -1.2, 1.6) in women and -1.2 (IQR: -2.2, 0.5) in men (p<0.0001). The prevalence of NAFLD was 67.4% among women and 39.5% among men (p<0.0001). The association between Atole exposure from conception to two years and NAFLD was not significant (OR: 0.90, 95% CI: 0.50-1.63). CONCLUSIONS: NAFLD prevalence among Guatemalan adults exceeds the global average. Protein-energy supplementation in early life was not associated with later NAFLD. There is a need for further studies on the causes and onset of NAFLD throughout the life course.
Authors: Makiko Yamada; Diana Wolfe; Guang Han; Samuel W French; Michael G Ross; Mina Desai Journal: Congenit Anom (Kyoto) Date: 2011-12 Impact factor: 1.409
Authors: Samuel Sandboge; Mia-Maria Perälä; Minna K Salonen; Paul A Blomstedt; Clive Osmond; Eero Kajantie; David J P Barker; Johan G Eriksson Journal: Ann Med Date: 2013-06-14 Impact factor: 4.709
Authors: Aml Erhuma; Andrew M Salter; Dean V Sculley; Simon C Langley-Evans; Andrew J Bennett Journal: Am J Physiol Endocrinol Metab Date: 2007-02-13 Impact factor: 4.310
Authors: Alvaro Rivera-Andrade; Jessica L Petrick; Christian S Alvarez; Barry I Graubard; Andrea A Florio; Maria F Kroker-Lobos; Dominick Parisi; Neal D Freedman; Mariana Lazo; Eliseo Guallar; John D Groopman; Manuel Ramirez-Zea; Katherine A McGlynn Journal: Aliment Pharmacol Ther Date: 2022-04-28 Impact factor: 9.524